Breast Cancer-Associated Gene 3 Interacts With Rac1 And Augments Nf-Kappa B Signaling In Vitro, But Has No Effect On Rankl-Induced Bone Resorption In Vivo

Breast cancer-associated gene 3 (BCA3) is a recently identified adaptor protein whose functions are still being defined. BCA3 has been reported to be an important regulator of nuclear factor-kappa B (NF-kappa B) signaling. It has also been reported to interact with the small GTPase, Rac1. Consistent with that observation, in the present study, BCA3 was found to interact with nuclear Rac1 in 293 cells and influence NF-kappa B signaling. Additional experiments revealed that depending on cell type, BCA3 augmented, attenuated or had no effect on NF-kappa B signaling in vitro. Since canonical NF-kappa B signaling is a critical downstream target from activated receptor activator of nuclear factor-kappa B (RANK) that is required for mature osteoclast formation and function, BCA3 was selectively overexpressed in osteoclasts in vivo using the cathepsin K promoter and the response to exogenous receptor activator of nuclear factor-kappa B ligand (RANKL) administration was examined. Despite its ability to augment NF-kappa B signaling in other cells, transgenic animals injected with high-dose RANKL had the same hypercalcemic response as their wild-type littermates. Furthermore, the degree of bone loss induced by a 2-week infusion of low-dose RANKL was the same in both groups. Combined with earlier studies, the data from our study data indicate that BCA3 can affect NF-kappa B signaling and that BCA3 plays a cell-type dependent role in this process. The significance of the BCA3/NF-kappa B interaction in vivo in bone remains to be determined.